AmerisourceBergen shells out $25M for Xcenda

AmerisourceBergen has acquired Xcenda, a pharmaceutical services firm, for $25 million. The company will be added to the AmerisourceBergen Specialty Group and will enhance the company's existing manufacturer services business. The release said that Xcenda will provide additional capabilities in the key areas of pharmaceutical brand services, applied health outcomes and biopharma strategies.

"The addition of Xcenda supports AmerisourceBergen's strategy of acquiring service companies within the pharmaceutical supply channel," said R. David Yost, the CEO of AmerisourceBergen.

- see the release on the buyout

Suggested Articles

J&J's EGFR-fighting combo stopped tumor growth in 60% of patients whose lung cancer got worse after taking AstraZeneca's Tagrisso.

Amgen's KRAS inhibitor curbed tumor growth in 88% of patients with non-small cell lung cancer, shrinking tumors in one-third of them.

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.